Literature DB >> 22077498

Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib.

Kazuma Ohyashiki, Sei-ichiro Katagiri, Tetsuzo Tauchi, Junko H Ohyashiki, Yasuhiro Maeda, Itaru Matsumura, Tai-ichi Kyo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22077498     DOI： 10.1111/j.1365-2141.2011.08939.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  25 in total

1.  Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.

Authors:  Mohamed El Missiry; Shady Adnan Awad; Hanna L Rajala; Ahmed Al-Samadi; Marja Ekblom; Berit Markevän; Ingbritt Åstrand-Grundström; Maren Wold; Ellen Rabben Svedahl; Birgitte Ravn Juhl; Ole Weis Bjerrum; Inger Haulin; Kimmo Porkka; Ulla Olsson-Strömberg; Henrik Hjorth-Hansen; Satu Mustjoki
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-08       Impact factor: 4.553

Review 2.  An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Authors:  Stephanie C Casey; Yulin Li; Dean W Felsher
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 3.  Immunology and immunotherapy of chronic myeloid leukemia.

Authors:  Mette Ilander; Can Hekim; Satu Mustjoki
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

Review 4.  Minimal Residual Disease Eradication in CML: Does It Really Matter?

Authors:  Srinivas K Tantravahi; Raga S Guthula; Thomas O'Hare; Michael W Deininger
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 5.  Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.

Authors:  Elias J Jabbour; Jorge E Cortes; Hagop M Kantarjian
Journal:  Expert Rev Anticancer Ther       Date:  2013-12       Impact factor: 4.512

Review 6.  Immunological off-target effects of imatinib.

Authors:  Laurence Zitvogel; Sylvie Rusakiewicz; Bertrand Routy; Maha Ayyoub; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2016-03-31       Impact factor: 66.675

7.  Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.

Authors:  Sung-Eun Lee; Soo Young Choi; Hye-Young Song; Soo-Hyun Kim; Mi-Yeon Choi; Joon Seong Park; Hyeoung-Joon Kim; Sung-Hyun Kim; Dae Young Zang; Sukjoong Oh; Hawk Kim; Young Rok Do; Jae-Yong Kwak; Jeong-A Kim; Dae-Young Kim; Yeung-Chul Mun; Won Sik Lee; Myung Hee Chang; Jinny Park; Ji Hyun Kwon; Dong-Wook Kim
Journal:  Haematologica       Date:  2016-02-17       Impact factor: 9.941

Review 8.  Noncanonical roles of the immune system in eliciting oncogene addiction.

Authors:  Stephanie C Casey; David I Bellovin; Dean W Felsher
Journal:  Curr Opin Immunol       Date:  2013-04-06       Impact factor: 7.486

Review 9.  Treatment-free remission in patients with chronic myeloid leukaemia.

Authors:  David M Ross; Timothy P Hughes
Journal:  Nat Rev Clin Oncol       Date:  2020-05-06       Impact factor: 66.675

Review 10.  Recent advances in understanding chronic myeloid leukemia: where do we stand?

Authors:  Rahul Kumar; Daniela S Krause
Journal:  Fac Rev       Date:  2021-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.